Clinical Trial Update: Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab plus bevacizumab and TP chemotherapy for high-risk locally advanced nasopharyngeal carcinoma; study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CISPLATIN (cisplatin)
• PACLITAXEL (PACLITAXEL)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Locally Advanced Nasopharyngeal Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING